立体定向放疗联合帕博利珠单抗和曲美替尼对比联合吉西他滨治疗术后局部复发胰腺癌的II期随机对照试验
这项开放标签、随机对照II期试验纳入170例KRAS突变且PD-L1阳性的术后局部复发胰腺导管腺癌患者,比较SBRT联合帕博利珠单抗和曲美替尼与SBRT联合吉西他滨的疗效。
要点
- 联合靶向免疫组3-4级转氨酶升高和胆红素升高更常见,联合化疗组中性粒细胞减少更常见。
- 联合靶向免疫组严重不良事件发生率为22%,未发生治疗相关死亡。
核心结论
- SBRT联合帕博利珠单抗和曲美替尼可能成为术后局部复发胰腺癌的新治疗选择,需III期试验验证。
研究设计与样本
- 开放标签、随机对照II期试验,在中国上海长海医院招募170例KRAS突变且PD-L1阳性的术后局部复发胰腺导管腺癌患者,1:1随机分组。
主要发现
- 联合靶向免疫组3-4级不良事件:转氨酶升高10例(12%),胆红素升高4例(5%),中性粒细胞减少1例(1%),血小板减少1例(1%)。
- 联合化疗组3-4级不良事件:转氨酶升高6例(7%),中性粒细胞减少9例(11%),血小板减少4例(5%)。
- 联合靶向免疫组严重不良事件19例(22%),联合化疗组12例(14%)。
临床怎么用
- 对于KRAS突变且PD-L1阳性的术后局部复发胰腺癌患者,可考虑SBRT联合帕博利珠单抗和曲美替尼作为治疗选项。
- 治疗期间需监测肝功能、血常规等不良事件,尤其是转氨酶和胆红素升高。
局限性
- II期试验样本量有限,结果需III期试验确认。
- 研究仅纳入KRAS突变且PD-L1阳性的患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is paucity of investigations into immunotherapy or targeted therapy for postoperative locally recurrent pancreatic cancer. We aimed to assess the efficacy of stereotactic body radiotherapy (SBRT) plus pembrolizumab and trametinib in these patients. METHODS: In this open-label, randomised, controlled, phase 2 study, participants were recruited from Changhai Hospital affiliated to Naval Medical University, Shanghai, China. Eligible patients were aged 18 years or older with histologically confirmed pancreatic ductal adenocarcinoma characterised by mutant KRAS and positive immunohistochemical staining of PD-L1, Eastern Cooperative Oncology Group performance status of 0 or 1, and documented local recurrence after surgery followed by chemotherapy (mFOLFIRINOX or 5-fluorouracil). Eligible participants were randomly assigned (1:1) using an interactive voice or web response system, without stratification, to receive SBRT with doses ranging from 35-40 Gy in five fractions, intravenous pembrolizumab 200 mg once every 3 weeks, and oral trametinib 2 mg once daily or SBRT (same regimen) and intravenous gemcitabine (1000 mg/m2) on day 1 and 8 of a 21-day cycle for eight cycles until disease progression, death, unacceptable toxicity, or consent withdrawal. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in the as-treated population in all participants who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT02704156, and is now complete. FINDINGS: Between Oct 10, 2016, and Oct 28, 2017, 198 patients were screen, of whom 170 patients were enrolled and randomly assigned to receive SBRT plus pembrolizumab and trametinib (n=85) or SBRT plus gemcitabine (n=85). As of the clinical cutoff date (Nov 30, 2020), median follow-up was 23·3 months (IQR 20·5-27·4). Median overall survival was 24·9 months (23·3-26·5) with SBRT plus pembrolizumab and trametinib and 22·4 months (95% CI 21·2-23·6) with SBRT plus gemcitabine (hazard ratio [HR] 0·60 [95% CI 0·44-0·82]; p=0·0012). The most common grade 3 or 4 adverse effects were increased alanine aminotransferase or aspartate aminotransferase (ten [12%] of 85 in SBRT plus pembrolizumab and trametinib group vs six [7%] of 85 in SBRT plus gemcitabine group), increased blood bilirubin (four [5%] vs none), neutropenia (one [1%] vs nine [11%]), and thrombocytopenia (one [1%] vs four [5%]). Serious adverse events were reported by 19 (22%) participants in the SBRT plus pembrolizumab and trametinib group and 12 (14%) in the SBRT plus gemcitabine group. No treatment-related deaths occurred. INTERPRETATION: The combination of SBRT plus pembrolizumab and trametinib could be a novel treatment option for patients with locally recurrent pancreatic cancer after surgery. Phase 3 trials are needed to confirm our findings. FUNDING: Shanghai Shenkang Center and Changhai Hospital. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Zhu X, Cao Y, Liu W, et al. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2021. PMID: 34237249. doi:10.1016/S1470-2045(21)00286-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。